Nevro Corp (NVRO) Forecasted to Post FY2017 Earnings of ($1.30) Per Share

Nevro Corp (NYSE:NVRO) – Equities researchers at William Blair lifted their FY2017 EPS estimates for shares of Nevro in a research note issued on Tuesday. William Blair analyst M. Kaczor now forecasts that the medical equipment provider will earn ($1.30) per share for the year, up from their prior forecast of ($1.47). William Blair also issued estimates for Nevro’s Q4 2017 earnings at ($0.20) EPS, Q1 2018 earnings at ($0.34) EPS, Q2 2018 earnings at ($0.23) EPS, Q3 2018 earnings at ($0.16) EPS, FY2018 earnings at ($0.92) EPS, Q1 2019 earnings at ($0.33) EPS, Q2 2019 earnings at ($0.13) EPS, Q4 2019 earnings at $0.04 EPS and FY2019 earnings at ($0.48) EPS.

Nevro (NYSE:NVRO) last released its quarterly earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.02. Nevro had a negative net margin of 7.57% and a negative return on equity of 10.30%. The company had revenue of $82.26 million for the quarter, compared to analyst estimates of $80.50 million. During the same quarter last year, the firm posted ($0.14) earnings per share. The company’s quarterly revenue was up 35.0% compared to the same quarter last year.

Other equities analysts have also issued research reports about the stock. BMO Capital Markets reissued a “buy” rating and issued a $100.00 price target on shares of Nevro in a research report on Thursday, December 14th. Canaccord Genuity reissued a “buy” rating and issued a $120.00 price target on shares of Nevro in a research report on Sunday, October 8th. Northland Securities restated a “buy” rating and issued a $96.00 price objective on shares of Nevro in a research note on Tuesday, November 7th. TheStreet upgraded shares of Nevro from a “d+” rating to a “c-” rating in a research note on Monday, November 6th. Finally, BidaskClub upgraded shares of Nevro from a “sell” rating to a “hold” rating in a research note on Saturday, October 7th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $99.25.

Nevro (NVRO) opened at $77.40 on Thursday. Nevro has a 52-week low of $65.00 and a 52-week high of $99.63. The company has a market cap of $2,290.00, a P/E ratio of -53.38 and a beta of -0.83. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81.

In other news, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total value of $525,770.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 12.10% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of NVRO. Ameritas Investment Partners Inc. boosted its stake in Nevro by 17.3% during the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after buying an additional 358 shares in the last quarter. PNC Financial Services Group Inc. acquired a new stake in Nevro during the second quarter worth $190,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Nevro during the third quarter worth $211,000. Prudential Financial Inc. boosted its stake in Nevro by 13.8% during the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock worth $214,000 after buying an additional 350 shares in the last quarter. Finally, Sterling Capital Management LLC acquired a new stake in Nevro during the second quarter worth $233,000.

WARNING: “Nevro Corp (NVRO) Forecasted to Post FY2017 Earnings of ($1.30) Per Share” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3145036/nevro-corp-nvro-forecasted-to-post-fy2017-earnings-of-1-30-per-share.html.

Nevro Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.